Wells Fargo & Company Monopar Therapeutics Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Monopar Therapeutics stock. As of the latest transaction made, Wells Fargo & Company holds 1,537 shares of MNPR stock, worth $1,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,537
Previous 37
4054.05%
Holding current value
$1,122
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding MNPR
# of Institutions
16Shares Held
390KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny192KShares$140,4380.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA45.2KShares$32,9710.0% of portfolio
-
Geode Capital Management, LLC Boston, MA41.2KShares$30,0750.0% of portfolio
-
Hrt Financial LP New York, NY32.1KShares$23,4420.0% of portfolio
-
Gerber, LLC Columbus, OH28KShares$20,4430.02% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $9.29M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...